

Dialysis Facility Report for Fiscal Year 2025

Purpose of the Report

The *Dialysis Facility Report (DFR) for Fiscal Year (FY) 2025* is provided as a resource for characterizing selected aspects of clinical experience at this facility relative to other dialysis facilities in this state, ESRD Network, and across the United States. Since these data could be useful in quality improvement and assurance activities, each state's surveying agency may utilize this report as a resource during the FY 2025 survey and certification process.

This report has been prepared for this facility by the University of Michigan Kidney Epidemiology and Cost Center (UM-KECC) with funding from the Centers for Medicare & Medicaid Services (CMS) and is based primarily on data reported in End Stage Renal Disease Quality Reporting System (EQRS), Medicare claims and data collected for CMS. It is the twenty-ninth in a series of annual reports. This is one of 1 reports that have been distributed to ESRD providers in the U.S.

This DFR includes data specific to CCN(s): 999999

Overview

This report includes summaries of patient characteristics, treatment patterns, and patient outcomes for chronic dialysis patients who were treated in this facility between January 2020 and December 2023. Mortality, hospitalization, transplantation, and waitlist statistics are reported for a three- or four-year period. Regional and national averages are included to allow for comparisons. Some of these summaries are adjusted to account for the characteristics of the patient mix at this facility, such as age, sex and diabetes as a cause of ESRD. Unless otherwise specified, summaries include all dialysis patients.

Selected facility highlights from this report are provided on pages 2 through 5 and key data elements that are updated quarterly appear in bold font. For a complete description of the methods used to calculate the statistics in this report, please see the *Guide to the Dialysis Facility Reports for FY 2025* available for download from the methodology section of the Dialysis Data website at www.DialysisData.org.

What's New This Year

The following changes have been incorporated into the DFR for FY 2025: (1) The Standardized Modality Switch Ratio for incident in-center hemodialysis patients (SMoSR) was added to Table 2. This measure provides an adjusted modality outcome for patients who in their first year of treatment switch to a home dialysis modality (PD or HHD). Switches to home dialysis in the first year reflect that the facility is providing effective access to modality education and resources that can support patient modality decisions. (2) The percentage of prevalent patients on the waitlist in active status was added to Table 6. This measure is similar to the age-adjusted percentage of patient-months waitlisted measure, but only includes patients in active status and provides information about the facilities' ongoing support, as patients can lapse from active status. (3) Tables C1 and C2 now provide COVID-19 patient counts, deaths, and hospitalizations among Medicare dialysis patients for each year of the reporting period. (4) Table footnotes that may be referenced across multiple tables have been moved to a new **Appendix** following the tables at the end of the report.

Data Limitations: The CMS COVID Extraordinary Circumstances Exception (ECE) data policy restricts the use of claims data from March-June 2020 and EQRS clinical data from January-June 2020. Table footnotes provide additional details of data availability for each measure in 2020.

How to Submit Comments

Between July 15, 2024 and August 15, 2024, facilities may submit comments to their state surveyor or UM-KECC by visiting www.DialysisData.org, logging on to view their report, and clicking on the **Comments & Inquiries** tab. Questions or comments after the comment period is over may be submitted to us directly at DialysisData@umich.edu.

- (1) **State Surveyor:** Select **"DFR: Comments on DFR for State Surveyor"** from the drop down list to submit comments regarding this report for the state's surveyor(s). Any comments submitted will be appended and sent to the state's surveyor(s) in September 2024. Please do not include questions for UM-KECC using this option.
- (2) **UM-KECC:** Select **"DFR: Comments on DFR for UM-KECC"** to submit questions or suggestions to improve the DFR to UM-KECC. These comments will not be shared with CMS or your state surveyor.




Facility Highlights

Bar charts in this section are displayed as a percentage for all measures reported and highlight the facility's value compared to the state, network, and US.

The line charts in this section are displayed for all standardized measures. The markers show the values of the corresponding standardized measure for this facility, state, network, and US. The bolded horizontal line shows the range of uncertainty due to random variation (95% confidence interval; significant if it does not cross the 1.0 reference line). Regional and national values are plotted above the dotted line to allow for comparisons to facility values.

Patient Characteristics (Tables 1 and 2):


- Among the 15 incident patients with Medical Evidence Forms (CMS-2728) indicating treatment at this facility during 2023:
 - 16% of these patients were not under the care of a nephrologist before starting dialysis, compared to 15% in your State, 15% in your Network, and 16% nationally.
 - 93% of these patients were informed of their transplant options, compared to 93% in your State, 93% in your Network, and 93% nationally.
- Among the patients treated at this facility on December 31, 2023, 13% were treated in a nursing home during the year, compared to 13% in your State, 13% in your Network, and 13% nationally.




Standardized Mortality Ratio (SMR) (Table 3):

- At this facility, the 2020-2023 SMR is 0.98, which is 2% fewer deaths than expected at this facility. Among all U.S. facilities, 50% of facilities had a four-year SMR lower than 0.98. This difference is not statistically significant ($p \geq 0.05$), so this lower mortality could plausibly be just a chance occurrence. The 2020-2023 SMR of observed to expected deaths is 0.97 and 0.97 for your State and Network, respectively.
- At this facility, the 2020-2022 first-year SMR of observed to expected deaths is 1.01, which is 48% more deaths than expected at this facility. Among all U.S. facilities, 50% of facilities had a first-year SMR lower than 1.01. This difference is not statistically significant ($p \geq 0.05$), so this higher mortality could plausibly be just a chance occurrence. The first-year SMR (2020-2022) of observed to expected deaths is 1.01 and 1.01 for your State and Network, respectively.

2020-2023 SMR



2020-2022 First-Year SMR



▼ Significantly Less than 1.0 ◆ Not Significantly Different than 1.0 ▲ Significantly Greater than 1.0

▼ Significantly Less than 1.0 ◆ Not Significantly Different than 1.0 ▲ Significantly Greater than 1.0


Dialysis Facility Report for Fiscal Year 2025

SAMPLE Dialysis Facility State: XX Network: 99 CCN: SAMPLE


Hospitalizations and Readmissions (Table 4):

- The 2020-2023 Standardized Hospitalization Ratio (SHR-Admissions) at this facility is 0.98, which is 2% fewer admissions hospitalized than expected. This difference is not statistically significant ($p \geq 0.05$), so this lower hospitalization could plausibly be just a chance occurrence. The 2020-2023 SHR (Admissions) for your State and Network is 0.98 and 0.99, respectively.
- The 2023 Standardized Readmission Ratio (SRR) at this facility is 1.00, which is equivalent to the national reference value. The 2023 SRR for your State and Network is 1.03 and 1.04, respectively.

2020-2023 SHR-Admissions





2020-2023 SRR



Infection (Tables 4 and 11):

- The percentage of Medicare dialysis patients at this facility hospitalized with septicemia during 2020-2023 is 12%, compared to 13% in your State, 13% in your Network, and 12% nationally.
- The 2023 rate of PD catheter-related infection was 2.8 per 100 PD patient-months, compared to 2.5 in your State, 2.5 in your Network, and 2.5 nationally.






Transplantation (Table 5):

- The 2020-2023 Standardized 1st Transplantation Ratio (STR) of observed to expected number of patients transplanted for this facility is 1.03, which is 3% higher than expected for this facility. This difference is not statistically significant ($p \geq 0.05$) and is plausibly due to random chance. The 2020-2023 STR for your State and Network is 1.05 and 1.04, respectively.

Transplant Waitlist (Table 6):

- The 2023 age-adjusted percent waitlisted at this facility is 16%, which equal to the national adjusted percentage. The age-adjusted percent waitlisted in your State and Network is 16% and 16%, respectively.
- At this facility, the 2020-2022 Standardized Waitlist Ratio (SWR) is 0.98, which is 2% fewer patients on the waitlist and living donor transplants than expected at this facility. This difference is not statistically significant ($p \geq 0.05$) and could plausibly be due to a chance occurrence. The 2020-2022 SWR for your State and Network is 1.05 and 1.03, respectively.






Influenza Vaccination (Table 7):

- Among the 60 dialysis patients treated at this facility on December 31, 2023, 76% were vaccinated between August 1 and December 31, 2023 compared to 78% nationally. This difference is not statistically significant ($p \geq 0.05$) and is plausibly due to random chance. The percentage of patients vaccinated in your State and Network is 77% and 78%, respectively.

Anemia Management (Table 8):

- In 2023, 23% of eligible hemodialysis patient-months had a hemoglobin value below 10 g/dL, compared to 23% in your State, 23% in your Network, and 23% nationally.
- In 2023, 22% of eligible peritoneal dialysis patient-months had a hemoglobin value below 10 g/dL, compared to 22% in your State, 22% in your Network, and 23% nationally.



Dialysis Facility Report for Fiscal Year 2025

SAMPLE Dialysis Facility State: XX Network: 99 CCN: SAMPLE

Dialysis Adequacy (Table 9):







- In 2023, 95% of eligible hemodialysis patient-months had a Kt/V ≥ 1.2 reported, compared to 97% in your State, 97% in your Network, and 97% nationally.
- In 2023, 89% of eligible peritoneal dialysis patient-months had a Kt/V ≥ 1.7 reported, compared to 92% in your State, 92% in your Network, and 92% nationally.

Mineral Metabolism (Table 10):

- In 2023, 16% of eligible patient-months had a serum phosphorus value >7.0 mg/dL, compared to 16% in your State, 16% in your Network, and 16% nationally.
- In 2023, 1.1% of eligible patient-months had calcium uncorrected value >10.2 mg/dL, compared to 1.0% in your State, 1.0% in your Network, and 1.0% nationally.

Vascular Access (Table 11):

- This facility's 2023 Standardized Fistula Rate (SFR) for prevalent patients is 58%, which is 0% higher than the national SFR. This difference is not statistically significant ($p \geq 0.05$) and could plausibly be due to a chance occurrence. The SFR in your State and Network is 58% and 58%, respectively.
- Of the prevalent patients receiving hemodialysis treatment at this facility in 2023, the long-term catheter rate was 19%, compared to 18% in your State, 18% in your Network, and 18% nationally.



Dialysis Facility Report for Fiscal Year 2025

SAMPLE Dialysis Facility State: XX Network: 99 CCN: SAMPLE

The tables below provide updates of COVID-19 patient counts, deaths, and hospitalizations among Medicare dialysis patients (Table C1) and Medicare nursing home (NH) dialysis patients (Table C2), 2020-2023. State, Network, and National averages for 2023 are reported for comparison.

TABLE C1. COVID among Medicare Dialysis Patients, 2020-2023^{*1}

Measure Name	This Facility				Regional Averages, 2023		
	2020	2021	2022	2023	State	Network	U.S.
1 Medicare dialysis patients (n)	34	49	72	70	n/a	n/a	n/a
2 Patients ever infected with COVID (n)	14	16	19	13	n/a	n/a	n/a
Patients ever infected with COVID (% of 1)	41.2	32.7	26.4	18.6	28.1	25.8	26.4
3 Patients initially infected with COVID (n)	11	11	2	2	n/a	n/a	n/a
Patients initially infected with COVID (% of 1)	32.4	22.4	2.8	2.9	5.4	5.5	5.2
<i>Deaths among Medicare patients</i>							
4 Deaths (n)	0.0	1.0	5.0	6.0	n/a	n/a	n/a
5 Deaths among patients ever infected with COVID (n)	0.0	1.0	2.0	1.0	n/a	n/a	n/a
Deaths among patients ever infected with COVID (% of 4)	.	100	40.0	16.7	37.6	33.9	33.9
<i>Hospitalizations among Medicare patients^{*2}</i>							
6 Hospitalizations (n)	18	29	37	42	n/a	n/a	n/a
7 Hospitalizations among patients ever infected with COVID (n)	8	11	11	9	n/a	n/a	n/a
Hospitalizations among patients ever infected with COVID (% of 6)	44.4	37.9	29.7	21.4	33.5	30.6	30.7

TABLE C2. COVID among Medicare Dialysis Patients Treated in Nursing Home (NH) Facilities, 2020-2023^{*1}

Measure Name	This Facility				Regional Averages, 2023		
	2020	2021	2022	2023	State	Network	U.S.
1 Medicare NH dialysis patients (n)	9	11	23	20	n/a	n/a	n/a
2 Patients ever infected with COVID (n)	7	4	7	4	n/a	n/a	n/a
Patients ever infected with COVID (% of 1)	77.8	36.4	30.4	20.0	39.5	37.3	37.5
3 Patients initially infected with COVID (n)	7	3	0	1	n/a	n/a	n/a
Patients initially infected with COVID (% of 1)	77.8	27.3	0.0	5.0	10.0	10.3	9.2
<i>Deaths among Medicare NH patients</i>							
4 Deaths (n)	0	0	0	0	n/a	n/a	n/a
5 Deaths among patients ever infected with COVID (n)	0	0	0	0	n/a	n/a	n/a
Deaths among patients ever infected with COVID (% of 4)	44.1	40.6	40.3
<i>Hospitalizations among Medicare NH patients^{*2}</i>							
6 Hospitalizations (n)	6	7	16	15	n/a	n/a	n/a
7 Hospitalizations among patients ever infected with COVID (n)	4	3	6	3	n/a	n/a	n/a
Hospitalizations among patients ever infected with COVID (% of 6)	66.7	42.9	37.5	20.0	40.6	38.4	37.7

n/a = not applicable

[*1] See *Guide, Section XIX* for detailed information regarding information reported in Tables C1 and C2. Includes patients with Medicare as primary insurer or with a Medicare Advantage plan. Table C2 includes patients who were treated in a nursing home at least one day during the year.

[*2] Hospitalization is defined as having at least one day in a hospital from Medicare inpatient claims during the reporting period.

Dialysis Facility Report for Fiscal Year 2025

SAMPLE Dialysis Facility State: XX Network: 99 CCN: SAMPLE

TABLE 1: Summaries for All Dialysis Patients Treated as of December 31st of Each Year^{*1}, 2020-2023

Measure Name	This Facility				Regional Averages ^{*A} , 2023		
	2020	2021	2022	2023	State	Network	U.S.
1a Patients treated on 12/31 (n)	60	58	57	57	59.1	59.2	59.3
1b Average age (years)	62.0	62.1	62.2	62.3	62.5	62.5	62.5
1c Age (% of 1a; sums to 100%)							
< 18	0.8	0.9	0.9	0.9	0.3	0.3	0.3
18-64	51.3	50.8	50.4	49.9	50.9	50.9	51.0
65+	47.8	48.3	48.7	49.2	48.9	48.8	48.7
1d Female (% of 1a)	42.3	42.1	41.9	41.7	41.9	41.9	41.8
1e Race (% of 1a; sums to 100%)							
African American	33.4	33.5	33.5	33.3	35.6	35.7	33.9
Asian/Pacific Islander	5.1	5.4	5.5	5.6	5.7	5.8	6.9
Native American	1.5	1.6	1.9	2.3	2.1	2.1	2.1
White	59.8	59.2	58.8	58.4	56.3	56.1	56.8
Other/Unknown/Missing	0.3	0.3	0.4	0.3	0.3	0.3	0.3
1f Ethnicity (% of 1a; sums to 100%)							
Hispanic	17.9	18.5	19.2	19.6	20.0	20.3	23.2
Non-Hispanic	82.0	81.4	80.7	80.2	79.9	79.7	76.8
Unknown	0.1	0.1	0.1	0.1	0.0	0.0	0.1
1g Primary Cause of ESRD (% of 1a; sums to 100%)							
Diabetes	45.2	44.4	43.9	43.4	43.8	43.9	44.7
Hypertension	29.9	30.2	30.3	30.4	31.1	31.1	30.6
Glomerulonephritis	9.8	9.5	9.2	8.9	9.0	9.0	8.9
Other/Unknown	14.6	15.4	16.0	16.5	15.6	15.5	15.3
Missing	0.4	0.5	0.6	0.7	0.5	0.5	0.5
1h Average duration of ESRD (years)	4.9	4.8	4.8	4.8	4.9	4.9	4.9
1i Years since start of ESRD (% of 1a; sums to 100%)							
< 1	16.8	18.0	17.5	17.5	17.0	16.9	16.8
1-2	18.0	17.3	18.5	18.0	17.8	17.8	17.7
2-3	13.6	13.9	13.4	14.2	14.2	14.2	14.2
3-6	25.7	25.1	25.0	24.9	25.0	25.0	25.2
6+	25.9	25.8	25.6	25.3	26.0	26.0	26.1
1j Nursing home patients (% of 1a) ^{*2}	12.9	13.2	13.2	13.4	13.3	13.3	13.0
1k Modality (% of 1a; sums to 100%)							
In-center hemodialysis	84.6	83.9	83.2	82.8	82.8	82.9	83.2
Home hemodialysis	2.6	2.9	3.2	3.4	3.8	3.8	3.5
Continuous ambulatory peritoneal dialysis	1.6	1.5	1.5	1.6	1.4	1.4	1.5
Continuous cycling peritoneal dialysis	10.8	11.3	11.7	11.8	11.6	11.6	11.5
Other modality	0.4	0.4	0.4	0.4	0.3	0.3	0.3

n/a = not applicable

[*A - *F] See **Appendix: Table Footnotes** on page 28.

[*1] See *Guide, Section IV* for detailed information regarding the summaries included in Table 1.

[*2] Includes patients who were also treated by a nursing facility at any time during the year according to the Nursing Home Minimum Dataset.

Dialysis Facility Report for Fiscal Year 2025

SAMPLE Dialysis Facility State: XX Network: 99 CCN: SAMPLE

TABLE 2: Characteristics of New Dialysis Patients ^{*1}, 2020-2023 (Form CMS-2728)

Measure Name	This Facility				Regional Averages ^{*A} , 2023			
	2020	2021	2022	2023	State	Network	U.S.	
<i>Patient Characteristics</i>								
2a	Total number of patients with forms (n)	15	15	15	15	15.9	15.9	15.9
2b	Average age (years [0-95]) ^{*2}	62.5	62.7	62.6	62.8	62.9	62.9	62.9
2c	Female (% of 2a)	41.6	41.9	41.5	41.4	41.3	41.4	41.2
2d	Race (% of 2a; sums to 100%)							
	African-American	29.0	28.9	29.3	28.5	29.0	28.9	27.8
	Asian/Pacific Islander	5.2	5.3	5.4	5.4	5.5	5.5	6.2
	Native American	1.5	1.8	2.6	3.8	3.5	3.5	3.7
	White	64.1	63.6	62.3	61.8	61.5	61.6	61.8
	Other/Unknown	0.2	0.3	0.4	0.5	0.4	0.5	0.5
2e	Hispanic (% of 2a)	16.8	17.3	17.6	18.3	18.2	18.5	20.4
2f	Primary cause of ESRD (% of 2a; sums to 100%)							
	Diabetes	46.2	45.0	43.7	43.3	44.0	44.2	44.6
	Hypertension	29.5	29.8	30.7	31.1	31.5	31.5	31.1
	Primary glomerulonephritis	6.5	6.0	6.1	5.9	5.9	5.8	5.9
	Other/Unknown	17.7	19.3	19.4	19.6	18.6	18.5	18.4
2g	Medical coverage (% of 2a; sums to 100%)							
	Employer group only	12.3	11.7	11.6	11.3	11.5	11.4	11.3
	Medicare only	36.8	44.7	45.5	45.3	44.9	44.9	44.4
	Medicaid only	14.6	14.9	15.0	15.0	14.8	14.8	15.3
	Medicare and Medicaid only	10.2	6.6	6.7	7.4	7.7	7.7	7.8
	Medicare and other	12.5	7.8	8.1	8.2	8.5	8.5	8.3
	Other/Unknown	8.3	9.5	8.9	9.0	8.9	8.9	9.1
	None	5.3	4.9	4.1	3.8	3.9	3.9	3.8
2h	Median body mass index (Median; Weight/Height ²)							
	Male	28.5	28.5	28.4	28.1	27.8	27.8	27.7
	Female	29.8	29.9	29.4	29.1	28.6	28.7	28.5
2i	Employment (% of 18-60 year olds in 2a)							
	Six months prior to ESRD treatment	34.5	33.4	36.3	36.3	36.9	36.7	36.8
	At first ESRD treatment	23.4	24.0	26.9	26.8	27.4	27.3	27.3
2j	Primary modality (% of 2a; sums to 100%)							
	Hemodialysis	87.3	87.2	86.2	85.8	84.9	84.9	85.1
	CAPD/CCPD	12.7	12.8	13.8	14.2	15.1	15.1	14.9
	Other/Unknown	0.0	0.0	0.0	0.0	0.0	0.0	0.0
2k	Number of incident hemodialysis patients (n)	13	13	13	12	13.5	13.5	13.6
2l	Access used at first outpatient dialysis (% of 2k; sums to 100%)							
	Arteriovenous fistula	14.1	13.0	13.3	14.1	13.1	13.1	13.1
	Arteriovenous graft	2.8	2.5	2.9	3.1	3.0	3.0	3.0
	Catheter	82.8	84.2	83.5	82.5	83.6	83.6	83.6
	Other/Unknown/Missing	0.3	0.3	0.3	0.3	0.3	0.3	0.3
2m	Arteriovenous fistula placed (% of 2k)	25.5	23.9	23.2	23.9	22.7	22.7	22.8
<i>Average Lab Values Prior to Dialysis ^{*2}</i>								
2n	Hemoglobin (g/dL [5-20])	9.3	9.4	9.3	9.3	9.3	9.3	9.3
2o	Serum albumin (g/dL [0.8-6.0])	3.3	3.4	3.4	3.4	3.4	3.4	3.4
2p	Serum creatinine (mg/dL [0-33])	6.6	6.5	6.6	6.5	6.5	6.5	6.5
2q	GFR (mL/min [0-30])	9.8	9.9	9.8	9.9	9.9	9.9	9.9

(continued)

Dialysis Facility Report for Fiscal Year 2025

SAMPLE Dialysis Facility State: XX Network: 99 CCN: SAMPLE

TABLE 2 (cont.): Characteristics of New Dialysis Patients^{*1}, 2020-2023 (Form CMS-2728)

Measure Name	This Facility				Regional Averages ^{*A} , 2023		
	2020	2021	2022	2023	State	Network	U.S.
<i>Care Prior to ESRD Therapy</i>							
2r	Received ESA prior to ESRD (% of 2a)	15.7	15.5	16.1	16.5	16.5	16.6
2s	Pre-ESRD nephrologist care (% of 2a; sums to 100%) ^{*B}						
	No	16.7	17.1	16.5	15.5	15.2	15.6
	Yes, < 6 months	18.0	18.5	19.0	19.4	19.0	19.0
	Yes, 6-12 months	19.3	18.7	18.7	18.8	18.7	18.6
	Yes, > 12 months	30.6	29.2	28.6	29.1	29.3	29.1
	Unknown/Missing	15.4	16.5	17.1	17.2	17.7	17.8
2t	Informed of transplant options (% of 2a)	84.6	91.2	92.7	92.9	93.1	93.0
2u	Patients not informed of transplant options (n)	2	1	1	1	1.1	1.1
2v	Reason not informed (% of 2u; may not sum to 100%) ^{*B}						
	Medically unfit	20.4	39.3	44.4	43.9	38.8	38.2
	Unsuitable due to age	9.1	0.0	0.0	0.1	0.0	0.0
	Psychologically unfit	1.7	0.0	0.0	0.0	0.0	0.0
	Patient declined information	1.6	7.3	11.8	7.6	6.9	7.1
	Patient has not been assessed	62.1	40.1	47.0	43.8	53.1	53.8
<i>Comorbid Conditions</i>							
2w	Pre-existing comorbidity (% yes of 2a)						
	Congestive heart failure	27.0	26.2	25.4	25.6	26.0	25.7
	Atherosclerotic heart disease	11.5	10.6	10.2	10.7	10.7	10.7
	Other cardiac disorder	20.2	20.3	19.7	20.9	21.0	20.7
	CVD, CVA, TIA	8.7	8.4	8.2	8.2	8.2	8.1
	Peripheral vascular disease	8.5	7.8	7.0	7.5	7.4	7.5
	History of hypertension	87.5	86.7	86.7	87.4	87.9	87.9
	Diabetes	63.7	63.8	62.8	62.8	63.4	63.7
	Diabetes on insulin	42.5	41.8	40.5	40.1	40.8	40.8
	COPD	8.9	8.5	7.9	7.7	7.7	7.5
	Current smoker	7.1	6.9	6.9	7.0	6.9	6.6
	Cancer	7.1	6.8	6.7	6.8	6.7	6.6
	Alcohol dependence	1.9	1.9	1.9	1.9	1.8	1.8
	Drug dependence	1.6	1.6	1.7	1.7	1.7	1.7
	Inability to ambulate	6.6	6.5	5.9	5.8	5.7	5.7
	Inability to transfer	3.5	3.4	3.1	3.0	3.0	3.1
2x	Average number of comorbid conditions	3.1	3.0	2.9	3.0	3.0	3.0
<i>Standardized Modality Switch Ratio (SMoSR)</i>							
		2020	2021	2022	2020-2022		2020-2022 ^{*A}
2y	Eligible patients (n)	14	14	14	42 ^{*C}	15.1	15.1
2z	Patient-years at risk (n)	9.8	10.1	9.7	29.5 ^{*C}	10.7	10.7
2aa	Number of modality switches (n)	1	1	1	4 ^{*C}	1.4	1.4
2ab	Expected number of modality switches (n)	1.4	1.4	1.4	4.1 ^{*C}	1.4	1.4
2ac	SMoSR (2aa/2ab) ^{*D}				1.86	1.05	1.04
2ad	P-value for SMoSR ^{*E}				0.501	n/a	n/a
2ae	Confidence interval for SMoSR ^{*E}						
	High (97.5% limit)				11.5	n/a	n/a
	Low (2.5% limit)				0.38	n/a	n/a

n/a = not applicable

[*A - *F] See **Appendix: Table Footnotes** on page 28.

[*1] See *Guide, Section V* for detailed information regarding the summaries included in Table 2.

[*2] For continuous variables, summaries include only values in range indicated in brackets.

Dialysis Facility Report for Fiscal Year 2025

SAMPLE Dialysis Facility State: XX Network: 99 CCN: SAMPLE

TABLE 3: Mortality Summary for All Dialysis Patients (2020-23) ^ & New Dialysis Patients (2020-22) *1 ^

Measure Name	This Facility					Regional Averages ^{*A}		
	2020 ^	2021	2022	2023	2020-2023 ^	State	Network	U.S.
<i>All Patients: Death Counts</i>						2020-2023 ^		
3a Patients (n)	83	83	82	81	329 ^{*C}	82.4	82.4	89.8
3b Patient-years (PY) at risk (n)	40.2	59.1	57.5	57.1	213.9 ^{*C}	53.6	53.6	54.8
3c Deaths (n)	8	12	11	10	41 ^{*C}	10.2	10.2	10.8
3d Expected deaths (n)	8.7	13.1	11.6	10.4	42.1 ^{*C}	10.5	10.5	10.8
3e Withdrawal from dialysis prior to death (% of 3c)	23.0	20.7	22.1	23.0	22.0	22.4	22.3	21.5
3f Death due to Infections (% of 3c)	10.3	10.2	9.8	9.5	10.0	9.9	10.0	9.9
Death due to Cardiac causes (% of 3c)	44.9	43.5	45.0	45.7	44.5	45.0	45.2	44.3
Death due to Liver disease (% of 3c)	1.3	1.2	1.3	1.3	1.3	1.3	1.3	1.2
3g Dialysis unrelated deaths (n; excluded from SMR)	0	0	0	0	0 ^{*C}	0.1	0.1	0.1
<i>All Patients: Standardized Mortality Ratio (SMR)</i>								
3h SMR (3c/3d) ^{*D, *2}	0.99	0.95	0.99	1.02	0.98	0.97	0.97	1.00
3i P-value for SMR ^{*E}	0.499	0.500	0.499	0.495	0.501	n/a	n/a	n/a
3j Confidence interval for SMR ^{*E}								
High (97.5% limit)	2.04	1.88	1.89	1.93	1.60	n/a	n/a	n/a
Low (2.5% limit)	0.45	0.50	0.50	0.48	0.61	n/a	n/a	n/a
3k SMR percentiles for this facility								
In this State	50	50	50	51	50	n/a	n/a	n/a
In this Network	50	50	50	51	50	n/a	n/a	n/a
In the U.S.	50	50	50	51	50	n/a	n/a	n/a
<i>New Patients: First-Year Death Counts</i>								
	2020 ^	2021	2022		2020-2022 ^	2020-2022 ^		
3l New patients (n)	15	15	15		45 ^{*C}	15.4	15.4	15.4
3m Patient-years (PY) at risk (n)	8.3	8.6	8.3		25.2 ^{*C}	8.6	8.6	8.6
3n Deaths (n)	2	3	2		7 ^{*C}	2.5	2.5	2.5
3o Expected deaths (n)	2.4	2.8	2.5		7.6 ^{*C}	2.5	2.5	2.5
3p Withdrawal from dialysis prior to death (% of 3n)	22.1	22.4	22.5		22.2	22.6	22.6	22.4
3q Death due to Infections (% of 3n)	9.4	9.3	9.1		9.2	9.1	9.1	9.2
Death due to Cardiac causes (% of 3n)	39.7	40.4	40.1		39.5	39.7	39.8	40.1
Death due to Liver disease (% of 3n)	2.1	2.3	2.4		2.2	2.3	2.3	2.3
<i>First-Year Standardized Mortality Ratio (FySMR)</i>								
3r FySMR (3n/3o) ^{*D, *2}	0.94	0.96	0.96		1.01	1.01	1.01	1.00
3s P-value for FySMR ^{*E}	0.498	0.491	0.500		0.497	n/a	n/a	n/a
3t Confidence interval for FySMR ^{*E}								
High (97.5% limit)	2.47	2.45	2.51		2.20	n/a	n/a	n/a
Low (2.5% limit)	0.35	0.36	0.35		0.41	n/a	n/a	n/a
3u FySMR percentiles for this facility								
In this State	50	50	50		50	n/a	n/a	n/a
In this Network	50	50	50		50	n/a	n/a	n/a
In the U.S.	50	49	50		50	n/a	n/a	n/a

n/a = not applicable

[^, *A - *F] See **Appendix: Table Footnotes** on page 28.

[*1] See *Guide, Section VI* for detailed information regarding the summaries included in Table 3.

[*2] The SMRs (3h, 3r) are not shown if there are fewer than 3 expected deaths.

Dialysis Facility Report for Fiscal Year 2025

SAMPLE Dialysis Facility State: XX Network: 99 CCN: SAMPLE

TABLE 4: Hospitalization Summary for Medicare Dialysis Patients^{*1}, 2020-2023[^]

Measure Name	This Facility					Regional Averages ^{*A} , per Year, 2020-2023 [^]			
	2020 [^]	2021	2022	2023	2020-2023 [^]	State	Network	U.S.	
<i>Medicare Dialysis Patients</i>									
4a	Medicare dialysis patients (n)	67	67	65	64	262 ^{*C}	65.8	65.8	71.0
4b	Patient-years (PY) at risk (n)	31.8	46.4	44.7	43.5	166.4 ^{*C}	41.7	41.7	42.3
<i>Standardized Hospitalization Ratio (SHR) for Days Hospitalized^{*2}</i>									
4c	Total days hospitalized (n)	361	517	515	489	1,882 ^{*C}	472.1	472.0	505.2
4d	Expected total days hospitalized (n)	402.5	564.7	559.6	536.2	1,979.8 ^{*C}	494.9	494.9	505.3
4e	SHR (Days) (4c/4d) ^{*D}	0.95	0.95	0.95	0.96	0.96	0.95	0.96	1.00
4f	P-value for SHR (Days) ^{*E}	0.498	0.504	0.500	0.505	0.498	n/a	n/a	n/a
4g	Confidence interval for SHR (Days) ^{*E}								
	High (97.5% limit)	1.96	1.97	1.95	1.96	1.72	n/a	n/a	n/a
	Low (2.5% limit)	0.55	0.55	0.57	0.56	0.64	n/a	n/a	n/a
4h	SHR (Days) percentiles for this facility								
	In this State	50	50	50	50	50	n/a	n/a	n/a
	In this Network	50	50	50	50	50	n/a	n/a	n/a
	In the U.S.	50	50	50	50	50	n/a	n/a	n/a
<i>Standardized Hospitalization Ratio (SHR) for Hospital Admissions^{*2, *3}</i>									
4i	Total admissions (n)	45	63	60	61	230 ^{*C}	57.6	57.6	59.8
4j	Expected total admissions (n)	48.7	66.5	63.3	65.8	234.4 ^{*C}	58.6	58.6	59.8
4k	SHR (Admissions) (4i/4j)^{*D}	0.99	0.99	0.98	0.98	0.98	0.98	0.99	1.00
4l	P-value for SHR (Admissions) ^{*E}	0.500	0.501	0.498	0.498	0.495	n/a	n/a	n/a
4m	Confidence interval for SHR (Admissions) ^{*E}								
	High (97.5% limit)	1.71	1.72	1.72	1.68	1.52	n/a	n/a	n/a
	Low (2.5% limit)	0.61	0.61	0.62	0.63	0.69	n/a	n/a	n/a
4n	SHR (Admissions) percentiles for this facility								
	In this State	50	50	50	50	50	n/a	n/a	n/a
	In this Network	50	50	50	50	50	n/a	n/a	n/a
	In the U.S.	50	50	50	50	50	n/a	n/a	n/a
4o	Diagnoses associated with hospitalization (% of 4a)								
	Septicemia	13.0	12.4	12.2	12.2	12.5	12.8	12.8	12.4
	Acute myocardial infarction	6.9	7.3	7.4	7.7	7.3	7.6	7.6	7.3
	Congestive heart failure	28.3	28.2	28.5	28.9	28.4	29.3	29.3	28.1
	Cardiac dysrhythmia	19.1	19.1	18.9	19.1	19.0	19.5	19.5	18.6
	Cardiac arrest	2.7	2.9	2.7	2.5	2.7	2.8	2.8	2.7
4p	One day admissions (% of 4i)	9.1	8.8	8.4	8.4	8.6	8.5	8.5	8.5
4q	Average length of stay (days per admission; 4c/4i)	7.6	7.8	8.1	7.8	7.8	7.8	7.8	8.1
4r	Admissions that originate in the ED (% of 4i)	80.3	82.7	83.4	83.2	82.5	84.7	84.9	85.2

(continued)

Dialysis Facility Report for Fiscal Year 2025

SAMPLE Dialysis Facility State: XX Network: 99 CCN: SAMPLE

TABLE 4 (cont.): Hospitalization Summary for Medicare Dialysis Patients^{*1}, 2020-2023[^]

Measure Name	This Facility					Regional Averages ^{*A} , per Year, 2020-2023 [^]			
	2020 [^]	2021	2022	2023	2020-2023 [^]	State	Network	U.S.	
<i>Standardized Emergency Department Encounter Ratio (SEDR)^{*2}</i>									
4s	Emergency department (ED) events (n)	32	37	32	27	127 ^{*C}	32.0	32.0	32.0
4t	Expected number of emergency department events (n)	34.4	38.9	33.5	28.8	129.6 ^{*C}	32.4	32.4	32.4
4u	SEDR (4s/4t) ^{*D}	1.03	1.04	1.04	1.05	1.02	0.99	0.99	1.00
4v	P-value for SEDR ^{*E}	0.505	0.503	0.506	0.503	0.501	n/a	n/a	n/a
4w	Confidence interval for SEDR ^{*E}								
	High (97.5% limit)	2.14	2.11	2.17	2.20	1.89	n/a	n/a	n/a
	Low (2.5% limit)	0.52	0.54	0.52	0.53	0.58	n/a	n/a	n/a
<i>Standardized Ratio of ED Encounters Occurring within 30 Days of Hospital Discharge (ED30)^{*2}</i>									
4x	Index discharges (n)	24	32	27	24	107 ^{*C}	27.2	27.2	27.1
4y	Total ED visits within 30 days of hospital discharge (n)	4	5	4	3	16 ^{*C}	4.1	4.1	4.1
4z	Expected total ED visits within 30 days of hospital discharge (n)	4.6	5.6	4.8	4.3	16.7 ^{*C}	4.2	4.2	4.2
4aa	ED30 Ratio (4y/4z) ^{*E}	1.07	1.05	1.06	1.07	1.04	1.03	1.03	1.02
4ab	P-value for ED30 Ratio ^{*E}	0.500	0.498	0.496	0.493	0.500	n/a	n/a	n/a
4ac	Confidence interval for ED30 Ratio ^{*E}								
	High (97.5% limit)	2.47	2.39	2.48	2.55	1.94	n/a	n/a	n/a
	Low (2.5% limit)	0.33	0.35	0.33	0.33	0.47	n/a	n/a	n/a
<i>Standardized Readmission Ratio (SRR)^{*2}</i>									
									2023
4ad	Index discharges (n)	36	58	56	56		59.7	59.7	59.8
4ae	Total readmissions (n)	10	15	15	15		15.8	15.8	15.8
4af	Expected total readmissions (n)	11	16	16	16		16.1	16.1	16.1
4ag	SRR (4ae/4af)^{*D}	1.00	0.99	1.00	1.00		1.03	1.04	1.04
4ah	P-value for SRR ^{*E}	0.501	0.502	0.499	0.499		n/a	n/a	n/a
4ai	Confidence interval for SRR ^{*E}								
	High (97.5% limit)	1.71	1.63	1.64	1.63		n/a	n/a	n/a
	Low (2.5% limit)	0.49	0.54	0.54	0.54		n/a	n/a	n/a

n/a = not applicable

[^, *A - *F] See **Appendix: Table Footnotes** on page 28.

[*1] See *Guide, Section VII* for detailed information regarding the summaries included in Table 4. SEDR and ED30 statistics include only patients with Medicare as primary insurer and exclude patients with Medicare Advantage plans. All other summaries include patients with Medicare as primary insurer or with Medicare Advantage plan.

[*2] SHRs and SEDR are not shown if there are less than five patient years at risk. SRR and ED30 ratios are not shown if fewer than 11 index discharges in the year.

[*3] Rows 4i-4n exclude index COVID hospitalizations, while rows 4p-4r include all admissions. Row 4o includes diagnoses in any position on a hospital inpatient claim.

Dialysis Facility Report for Fiscal Year 2025

SAMPLE Dialysis Facility State: XX Network: 99 CCN: SAMPLE

TABLE 5: Transplantation Summary for Dialysis Patients under Age 75^{*1}, 2020-2023[^]

Measure Name	This Facility					Regional Averages ^{*A} , per Year, 2020-2023 [^]		
	2020 [^]	2021	2022	2023	2020-2023 [^]	State	Network	U.S.
<i>All Transplants</i>								
5a Eligible patients (n)	66	67	65	64	262 ^{*C}	65.6	65.6	71.7
5b Transplants (n)	2	2	2	3	9 ^{*C}	2.2	2.2	2.2
5c Donor type (sums to 5b) ^{*B}								
Living donor (n)	0	0	0	0	2 ^{*C}	0.4	0.4	0.4
Deceased donor (n)	1	2	2	2	7 ^{*C}	1.8	1.8	1.8
<i>First Transplants</i>								
5d Eligible patients (n)	62	62	61	60	245 ^{*C}	61.3	61.3	66.7
5e Patient years (PY) at risk (n)	30.0	44.3	42.8	42.0	159.2 ^{*C}	39.9	39.9	40.9
5f First transplants (n) ^{*2}	1	2	2	2	8 ^{*C}	2.0	2.0	2.0
5g Expected first transplants (n)	1.4	2.1	2.2	2.3	7.8 ^{*C}	1.9	1.9	1.9
<i>Standardized 1st Transplantation Ratio (STR)^{*3}</i>								
5h STR (5f/5g) ^{*D}					1.03	1.05	1.04	1.00
5i P-value for STR ^{*E}					0.398	n/a	n/a	n/a
5j Confidence interval for STR ^{*E}								
High (97.5% limit)					2.06	n/a	n/a	n/a
Low (2.5% limit)					0.48	n/a	n/a	n/a
5k STR percentiles for this facility								
In this State					51	n/a	n/a	n/a
In this Network					50	n/a	n/a	n/a
In the U.S.					50	n/a	n/a	n/a

n/a = not applicable

[^, *A - *F] See **Appendix: Table Footnotes** on page 28.

[*1] See *Guide, Section VIII* for detailed information regarding the summaries included in Table 5.

[*2] Among first transplants that occurred after the start of dialysis from 2020-2023, 3.1% of transplants in the U.S. were not included because the transplant occurred fewer than 91 days after the start of ESRD and 0.7% were not included because the patient was not assigned to a facility at time of transplant.

[*3] This section is calculated for the 4-year period only and not reported if there are fewer than 3 expected transplants.

Dialysis Facility Report for Fiscal Year 2025

SAMPLE Dialysis Facility State: XX Network: 99 CCN: SAMPLE

TABLE 6: Waitlist Summary for All Dialysis Patients (2020-2023) ^ & New Dialysis Patients (2020-2022) ^*1

Measure Name	This Facility				Regional Averages ^{*A} , 2023			
	2020 ^	2021	2022	2023	State	Network	U.S.	
<i>All Dialysis Patients under Age 75</i>								
6a	Eligible patients (n)	64	66	64	62	62.6	62.7	62.7
6b	Patient-months at risk (n) ^{*F}	378	557	538	529	530.4	530.6	530.8
6c	Patient-months on the waitlist (% of 6b) ^{*F}	17.0	16.5	16.3	16.0	16.2	16.1	16.5
6d	Patient-months on the waitlist by subgroup (%) ^{*F, *2}							
	Age < 40	25.4	24.8	24.1	23.9	24.9	24.8	25.1
	Age 40-74	15.9	15.5	15.3	14.9	15.2	15.1	15.5
	Male	18.0	17.6	17.4	17.0	17.3	17.1	17.7
	Female	15.3	15.0	14.8	14.4	14.7	14.6	14.9
	African American	17.2	16.9	16.7	16.2	15.9	15.8	15.7
	Asian/Pacific Islander	24.7	23.8	24.0	23.7	24.1	23.6	24.3
	Native American	14.7	14.5	14.0	12.9	13.5	13.3	11.6
	White, Hispanic	18.3	17.3	16.2	16.1	15.2	14.9	16.5
	White, non-Hispanic	16.6	16.2	15.8	15.5	16.3	16.2	16.2
	Other/unknown race	16.4	15.5	15.9	15.7	15.6	15.1	15.6
	Diabetes	14.0	13.7	13.8	13.6	13.7	13.5	14.0
	Non-diabetes	19.3	18.7	18.3	17.8	18.2	18.2	18.6
	Previous kidney transplant	29.3	28.8	27.8	26.8	27.5	27.5	28.0
	No previous kidney transplant	16.0	15.6	15.5	15.2	15.4	15.2	15.7
	< 2 years since start of ESRD	12.5	12.2	12.7	12.6	13.4	13.3	13.3
	2-4 years since start of ESRD	21.5	21.1	21.0	20.7	20.9	20.7	21.3
	5+ years since start of ESRD	18.1	17.4	16.6	15.8	15.0	14.9	15.8
6e	Age-adjusted percentage of patient-months waitlisted ^{*3}	17.0	16.6	16.4	16.0	16.0	16.0	16.0
6f	P-value for percent waitlisted ^{*E}	0.482	0.488	0.488	0.494	n/a	n/a	n/a
6g	Confidence interval for percent waitlisted ^{*E}							
	High (97.5% limit)	44.0	43.7	43.5	42.9	n/a	n/a	n/a
	Low (2.5% limit)	6.2	5.9	5.8	5.6	n/a	n/a	n/a
<i>Dialysis Patients in Active Status on the Waitlist</i>								
6h	Patient-months on the waitlist in active status (% of 6b) ^{*F}	10.8	10.1	9.6	9.3	9.5	9.4	9.7
6i	Age-adjusted percentage of patient-months waitlisted in active status ^{*3}	10.9	10.3	9.6	9.4	9.3	9.3	9.4
6j	P-value for percent waitlisted in active status ^{*E}	0.505	0.509	0.513	0.522	n/a	n/a	n/a
6k	Confidence interval for percent waitlisted in active status ^{*E}							
	High (97.5% limit)	36.5	35.6	34.7	34.1	n/a	n/a	n/a
	Low (2.5% limit)	3.4	3.1	2.8	2.7	n/a	n/a	n/a
<i>New Dialysis Patients: Standardized Waitlist Ratio (SWR) ^{*4}</i>								
		2020 ^	2021	2022	2020-2022 ^	2020-2022 ^{*A} ^		
6l	Eligible patients (n)	10	10	10	30 ^{*C}	10.4	10.4	10.4
6m	Patient-years (PY) at risk (n)	7.9	9.2	8.9	26.0 ^{*C}	8.9	8.9	8.9
6n	First waitlist events (n) ^{*4}	1	1	1	3 ^{*C}	0.9	0.9	0.9
6o	Expected 1st waitlist events (n) ^{*4}	0.8	1.0	1.0	2.6 ^{*C}	0.9	0.9	0.9
6p	SWR (6n/6o) ^{*D}				0.98	1.05	1.03	1.00
6q	P-value for SWR ^{*E}				0.492	n/a	n/a	n/a
6r	Confidence interval for SWR ^{*E}							
	High (97.5% limit)				2.66	n/a	n/a	n/a
	Low (2.5% limit)				0.31	n/a	n/a	n/a

n/a = not applicable

[^, *A - *F] See **Appendix: Table Footnotes** on page 28. [*1] See *Guide, Section IX* for detailed information regarding the summaries included in Table 6. Eligible patient-months (6b) include patients assigned to the facility on the last day of each month. [*2] The waitlist percentage for each subgroup is calculated rate of waitlisted patient-months to patient-months at risk in each subgroup. A missing value indicates that there were no eligible patients in the subgroup. [*3] Age-adjusted percentages of prevalent patients waitlisted (6e,6i) is not shown if there are fewer than 11 eligible patients in this facility. [*4] An event is defined as a waitlisting or living-donor transplant. SWR is not shown if a facility has less than 2 expected waitlisted events or less than 11 eligible patients.

Dialysis Facility Report for Fiscal Year 2025

SAMPLE Dialysis Facility State: XX Network: 99 CCN: SAMPLE

TABLE 7: Influenza Vaccination Summary for All Dialysis Patients*¹
Flu Seasons during August 2020 - December 2023

Measure Name	This Facility				Regional Averages* ^A		
	2020	2021	2022	2023	State	Network	U.S.
							2023
7a Eligible patients on Dec. 31 (n)	63	62	61	60	60.6	60.6	60.6
7b Patients excluded due to medical contraindication (n)	1	1	1	1	1.1	1.1	1.1
<i>Full Flu Season (Aug. 1-Mar. 31 of following year)</i>							2022
7c Patients vaccinated (% of 7a)	86.8	82.8	80.5		81.6	81.6	81.7
7d P-value* ^E (for 7c compared to U.S. value* ³)	0.186	0.173	0.165		n/a	n/a	n/a
7e Reason for no vaccination (% of 7a)							
Declined vaccination	6.8	8.4	8.3		8.5	8.5	8.3
Other reason or vaccine data not available	6.4	8.8	11.1		10.0	9.9	10.0
<i>Half Flu Season (Aug. 1-Dec. 31)</i>							2023
7f Patients vaccinated (% of 7a)	86.2	81.6	79.5	76.3	77.5	77.5	77.7
7g P-value* ^E (for 7f compared to U.S. value* ³)	0.184	0.171	0.162	0.158	n/a	n/a	n/a
7h Patients vaccinated by subgroup (%) * ⁴							
Medicare	87.1	82.8	80.8	78.0	78.8	78.9	79.0
Medicare Advantage	87.9	83.9	82.0	79.1	79.7	79.8	80.0
Medicare as primary insurer	86.8	82.1	80.0	77.3	77.9	77.9	78.1
Non-Medicare	80.5	74.4	73.2	69.4	70.4	70.6	71.6
Dual Medicare/Medicaid eligible	85.9	81.1	79.5	77.1	77.1	77.1	77.4
Age < 18	78.0	70.3	62.4	57.1	59.6	60.5	59.8
Age 18-39	79.5	71.7	70.5	66.9	66.6	66.7	67.0
Age 40-64	84.9	79.7	77.6	73.8	74.4	74.4	74.8
Age 65-74	88.0	84.2	82.4	79.7	80.3	80.3	80.4
Age 75+	89.4	86.2	84.9	82.7	83.5	83.6	83.5
Male	86.0	81.4	79.2	75.8	76.7	76.7	76.9
Female	86.5	82.2	80.6	77.9	78.4	78.4	78.6
African American	83.0	78.5	77.5	73.6	72.9	72.5	73.3
Asian/Pacific Islander	90.4	85.6	84.4	81.8	82.5	82.6	82.9
Native American	87.5	81.0	76.6	74.5	74.4	76.2	78.4
White	87.6	82.8	80.5	77.6	79.0	79.2	79.5
Other/unknown race	55.0	54.1	52.9	67.7	67.0	67.1	68.5
Hispanic	88.1	83.4	81.7	79.5	80.8	81.1	81.6
< 1 year since start of ESRD	80.8	74.9	72.2	70.0	69.8	69.9	69.9
1-2 years since start of ESRD	87.0	82.4	80.3	76.3	76.5	76.5	76.7
3+ years since start of ESRD	88.2	84.5	83.1	80.1	81.3	81.4	81.5

n/a = not applicable

[*A - *F] See **Appendix: Table Footnotes** on page 28.

[*1] See *Guide, Section X* for detailed information regarding the summaries included in Table 7. All Dialysis Patients are those treated on December 31st of the reporting year.

[*2] Compared to the U.S. value for that year and time period (8/1-3/31): 86.9% (2020), 83.3% (2021), 81.7% (2022).

[*3] Compared to the U.S. value for that year and time period (8/1-12/31): 86.3% (2020), 82.1% (2021), 80.6% (2022), 77.7% (2023).

[*4] A missing value indicates that there were no eligible patients in the subgroup.

Dialysis Facility Report for Fiscal Year 2025

SAMPLE Dialysis Facility State: XX Network: 99 CCN: SAMPLE

TABLE 8: Anemia Management Summaries for Adult Dialysis Patients ^{*1}, 2020-2023 [^]

Measure Name	This Facility				Regional Averages ^{*A}		
	2020 [^]	2021	2022	2023	State	Network	U.S.
<i>Hemoglobin and ESA for Adult Hemodialysis (HD) Patients</i>							
							2023
8a Eligible HD patients (n)	60	69	68	67	72.2	72.3	72.3
8b Eligible HD patient-months (n) ^{*F}	307	598	579	573	621.5	622.4	622.8
8c Average hemoglobin (g/dL) (average of 8b)	10.8	10.7	10.7	10.7	10.7	10.7	10.7
8d Hemoglobin categories (% of 8b; sums to 100%)							
<10 g/dL	22.3	23.1	23.4	23.0	23.1	23.1	23.0
10-<11 g/dL	33.1	33.1	33.0	31.9	32.8	32.8	32.9
11-12 g/dL	28.8	27.6	27.6	28.7	29.4	29.4	29.4
>12 g/dL	13.3	12.2	12.0	12.7	12.6	12.5	12.5
Missing/Out of range	2.6	4.0	4.1	3.7	2.1	2.1	2.2
8e ESA prescribed (% of 8b)	75.0	75.3	74.5	75.3	76.3	76.3	76.2
<i>Hemoglobin and ESA for Adult Peritoneal Dialysis (PD) Patients</i>							
8f Eligible PD patients (n)	8	11	10	11	24.3	23.9	23.8
8g Eligible PD patient-months (n) ^{*F}	40	81	81	82	189.2	186.8	185.6
8h Average hemoglobin (g/dL) (average of 8g)	10.9	10.9	10.9	11.0	11.0	11.0	11.0
8i Hemoglobin categories (% of 8g; sums to 100%)							
<10 g/dL	22.3	21.8	22.6	22.4	22.4	22.4	22.6
10-<11 g/dL	28.0	27.8	27.5	26.6	27.3	27.3	27.5
11-12 g/dL	26.3	25.8	25.4	26.0	26.6	26.6	26.5
>12 g/dL	19.8	19.5	19.4	20.6	20.6	20.6	20.2
Missing/Out of range	3.6	5.1	5.1	4.5	3.0	3.0	3.2
8j ESA prescribed (% of 8g)	55.1	53.8	53.2	53.4	54.0	54.0	54.4
<i>Standardized Transfusion Ratio (STrR)</i>							
	2020 [^]	2021	2022	2023			2023
8k Eligible adult Medicare patients (n)	41	34	30	26	27.7	27.8	27.8
8l Patient years (PY) at risk (n)	18	21	18	15	15.8	15.8	15.9
8m Total transfusions (n)	6	7	6	5	5.0	5.0	5.0
8n Expected total transfusions (n)	6.5	7.5	6.1	5.2	5.2	5.2	5.2
8o STrR (8m/8n) ^{*D, *E}	0.97	0.96	0.95	0.95	0.98	0.97	1.00
8p P-value for STrR ^{*E}	0.500	0.500	0.497	0.501	n/a	n/a	n/a
8q Confidence interval for STrR ^{*E}							
High (97.5% limit)	3.17	3.30	3.44	3.55	n/a	n/a	n/a
Low (2.5% limit)	0.42	0.42	0.41	0.40	n/a	n/a	n/a

n/a = not applicable

[^, *A - *F] See **Appendix: Table Footnotes** on page 28.

[*1] See *Guide, Section XI* for detailed information regarding the summaries included in Table 8. Transfusion summaries include adult Medicare dialysis patients only and not shown if there are fewer than 10 patient-years at risk (8l).

Dialysis Facility Report for Fiscal Year 2025

SAMPLE Dialysis Facility State: XX Network: 99 CCN: SAMPLE

TABLE 9: Dialysis Adequacy Summaries for Adult Dialysis Patients^{*1}, 2020-2023[^]

Measure Name	This Facility				Regional Averages ^{*A} , 2023		
	2020 [^]	2021	2022	2023	State	Network	U.S.
Hemodialysis (HD) Adequacy							
9a Eligible adult HD patients (n)	60	69	68	67	72.2	72.3	72.3
9b Eligible adult HD patient-months (n) ^{*F}	307	598	579	573	621.5	622.4	622.8
9c Average serum albumin (g/dL) (average of 9b)	3.9	3.9	3.9	3.9	3.9	3.9	3.9
9d Serum albumin categories (% of 9b; sums to 100%)							
< 3.0 g/dL	2.5	2.2	1.9	1.8	1.8	1.8	1.7
3.0-<3.5 g/dL	9.7	8.8	8.2	8.0	8.0	8.0	7.9
3.5-<4.0 g/dL	40.5	36.2	36.6	39.1	40.0	40.0	39.6
>=4.0 g/dL	43.5	47.7	47.9	46.5	47.2	47.1	47.6
Missing	3.7	5.0	5.4	4.7	3.0	3.0	3.1
9e Serum albumin<4.0 g/dl (% of 9b)	52.7	47.3	46.7	48.8	49.8	49.8	49.3
9f Ultrafiltration rate average (ml/kg/hr) (average of 9b)	7.6	7.6	7.6	7.5	7.7	7.6	7.7
9g Ultrafiltration rate categories (% of 9b; sums to 100%)							
<=13 ml/kg/hr	85.4	84.9	84.3	84.6	86.4	86.5	86.3
>13 ml/kg/hr	7.6	7.5	7.5	7.3	7.7	7.7	7.8
Out of Range (=20 ml/kg/hr)	2.4	2.3	2.4	2.6	2.5	2.5	2.4
Missing	4.6	5.3	5.7	5.5	3.4	3.4	3.5
9h Eligible adult HD Kt/V patients (n)	56	65	64	62	69.8	69.8	69.9
9i Eligible adult HD Kt/V patient-months (n) ^{*F}	287	558	540	532	595.1	595.7	596.3
9j Average Kt/V ^{*4} (average of 9i) ^{*2}	1.6	1.6	1.6	1.6	1.6	1.6	1.6
9k Kt/V categories (% of 9i; sums to 100%) ^{*2}							
<1.2	2.0	2.3	2.7	2.5	1.5	1.5	1.5
1.2-<1.8	70.7	70.6	71.6	69.4	70.1	70.1	69.9
>=1.8	25.7	24.3	22.7	25.6	26.9	26.9	27.0
Missing/Out of range	1.6	2.9	3.0	2.5	1.5	1.5	1.6
Peritoneal Dialysis (PD) Adequacy							
9l Eligible adult PD patients (n)	8	11	10	11	24.3	23.9	23.8
9m Eligible adult PD patient-months (n) ^{*F}	40	81	81	82	189.2	186.8	185.6
9n Average weekly Kt/V (average of 9m) ^{*2}	2.2	2.2	2.2	2.2	2.2	2.2	2.2
9o Weekly Kt/V categories (% of 9m; sums to 100%) ^{*2}							
<1.7	5.4	6.1	6.2	5.8	4.9	4.9	5.0
1.7-<2.5	67.6	65.7	65.3	65.0	67.4	67.4	67.5
>=2.5	23.1	23.5	23.5	24.2	24.5	24.5	24.1
Missing/Out of range	3.9	4.7	5.0	5.0	3.2	3.2	3.4
9p Average serum albumin (g/dL) (average of 9m)	3.6	3.7	3.7	3.7	3.7	3.7	3.7
9q Serum albumin categories (% of 9m; sums to 100%)							
< 3.0 g/dL	7.4	6.6	5.9	5.1	5.1	5.1	4.9
3.0-<3.5 g/dL	24.0	21.5	20.7	19.8	20.5	20.6	20.2
3.5-<4.0 g/dL	42.4	40.3	41.8	43.6	44.4	44.4	44.4
>=4.0 g/dL	22.5	26.6	26.5	27.0	26.8	26.8	27.2
Missing	3.7	5.0	5.0	4.6	3.1	3.1	3.3
9r Serum albumin <4.0 g/dL(% of 9m)	73.8	68.4	68.5	68.4	70.0	70.1	69.5

n/a = not applicable

[^, *A - *F] See **Appendix: Table Footnotes** on page 28.

[*1] See *Guide, Section XII* for detailed information regarding the summaries included in Table 9.

[*2] Kt/V summaries are supplemented with Medicare claims if missing in EQRS. HD Kt/V summaries are restricted to patients who dialyze thrice weekly. See section of Guide titled "*Determination of Thrice Weekly Dialysis*" for more information. The most recent value over a 4-month period is selected for PD Kt/V. PD Kt/V values for 2020 are calculated for quarter 4 only due to data exceptions.

Dialysis Facility Report for Fiscal Year 2025

SAMPLE Dialysis Facility State: XX Network: 99 CCN: SAMPLE

TABLE 10: Mineral Metabolism Summaries for All Adult Dialysis Patients ^{*1}, 2020-2023 [^]

Measure Name	This Facility				Regional Averages ^{*A} , 2023		
	2020 [^]	2021	2022	2023	State	Network	U.S.
10a Eligible adult patients (n)	68	78	77	76	80.3	80.4	80.6
10b Eligible adult patient-months (n) ^{*F}	347	681	662	657	693.6	694.4	695.8
10c Average Phosphorus (mg/dL) ^{*2}	5.5	5.5	5.5	5.5	5.5	5.5	5.5
10d Phosphorus categories (% of 10b; sums to 100%) ^{*2}							
<3.5 mg/dL	7.1	6.7	7.2	7.1	7.4	7.4	7.4
3.5-4.5 mg/dL	22.5	21.6	22.2	22.0	22.3	22.3	22.3
4.6-5.5 mg/dL	29.3	28.6	27.8	27.0	27.4	27.4	27.4
5.6-7.0 mg/dL	22.1	22.1	22.0	23.3	23.8	23.8	23.7
>7.0 mg/dL	15.5	16.1	15.8	16.2	16.4	16.4	16.3
Out of Range (<0.01 mg/dL or >20 mg/dL)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Missing	3.5	4.9	5.0	4.4	2.8	2.8	2.9
10e Average calcium uncorrected (mg/dL) (average of 10b)	8.9	8.9	8.9	8.9	8.8	8.8	8.8
10f Calcium uncorrected categories (% of 10b; sums to 100%)							
<8.4 mg/dL	19.6	18.1	18.5	19.9	20.3	20.2	20.3
8.4-10.2 mg/dL	76.0	76.1	75.7	74.8	76.2	76.2	76.1
>10.2 mg/dL	1.2	1.3	1.2	1.1	1.0	1.0	1.0
Out of Range (<0.01 mg/dL or >20 mg/dL)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Missing	3.2	4.5	4.6	4.2	2.6	2.6	2.7
10g Average uncorrected serum or plasma calcium > 10.2 mg/dL (%) ^{*3}	2.5	3.4	3.3	3.2	1.8	1.8	1.9

n/a = not applicable

[^, *A - *F] See **Appendix: Table Footnotes** on page 28.

[*1] See *Guide, Section XIII* for detailed information regarding the summaries included in Table 10.

[*2] Eligible patients included in the phosphorus summaries differ slightly from what is reported in 10b since it includes patient-months within the first 90 days of ESRD.

[*3] Hypercalcemia is averaged from uncorrected serum or plasma calcium values over a rolling 3-month period. Eligible patients included in the hypercalcemia summary differs slightly from what is reported in 10b since patients must be 18 years old as of the first day of the 3-month period. Missing or out of range values are counted towards the numerator.

Dialysis Facility Report for Fiscal Year 2025

SAMPLE Dialysis Facility State: XX Network: 99 CCN: SAMPLE

TABLE 11: Vascular Access Information for All Dialysis Patients and Access-Related Infection Summaries for All Medicare Patients ^{*1}, 2020-2023 [^]

Measure Name	This Facility				Regional Averages ^{*A}			
	2020 [^]	2021	2022	2023	State	Network	U.S.	
Vascular Access					2023			
11a	Prevalent adult hemodialysis patients (n)	63	73	71	70	75.7	75.9	75.9
11b	Prevalent adult hemodialysis patient-months (n) ^{*F, *2}	319	623	603	594	643.8	644.8	645.3
11c	Vascular access type in use (% of 11b; sums to 100%)							
	Arteriovenous fistula	61.0	59.0	57.8	57.2	58.2	58.1	58.7
	Arteriovenous graft	16.6	16.2	15.8	15.9	16.7	16.7	16.3
	Catheter	19.9	20.7	22.3	23.3	23.2	23.3	23.0
	Other/Missing	2.5	4.0	4.1	3.6	1.9	1.9	2.0
11d	Standardized Fistula Rate (SFR) ^{*D, *3}	61.9	60.2	59.0	58.4	58.3	58.4	58.3
11e	P-value for SFR ^{*E}	0.510	0.510	0.511	0.513	n/a	n/a	n/a
11f	Confidence interval for SFR ^{*E}							
	High (97.5% limit)	37.9	35.3	34.2	33.7	n/a	n/a	n/a
	Low (2.5% limit)	83.9	82.1	81.3	81.1	n/a	n/a	n/a
11g	Long-Term Catheter Rate ^{*4}	14.8	16.2	17.9	19.0	18.0	18.1	17.9
Vascular Access at First Treatment								
11h	Incident hemodialysis patients (n)	7	13	13	13	14.4	14.5	14.5
11i	Vascular access type in use (% of 11h; sums to 100%)							
	Arteriovenous fistula	13.2	13.2	13.1	13.2	12.4	12.4	12.5
	Arteriovenous graft	3.0	2.9	3.3	3.5	3.4	3.3	3.3
	Catheter	81.5	82.3	81.8	78.9	80.2	80.3	80.2
	Other/Missing	2.4	1.6	1.8	4.4	4.0	4.0	4.0
11j	Arteriovenous fistulae in place (% of 11h) ^{*5}	13.8	13.9	13.8	14.0	13.1	13.1	13.1
Infection: Peritoneal dialysis (PD)								
		2020 [^]	2021	2022	2023			2023
11k	Eligible PD patients (n)	6	6	5	5	10.4	10.2	10.1
11l	Eligible PD patient-months ^{*F}	31	41	37	33	71.4	70.2	69.8
11m	PD catheter infection rate per 100 PD patient-months	2.68	2.73	2.68	2.77	2.49	2.48	2.45
11n	P-value ^{*E} of 11m (compared to U.S. value) ^{*6}	0.405	0.374	0.392	0.392	n/a	n/a	n/a

n/a = not applicable

[^, *A - *F] See **Appendix: Table Footnotes** on page 28.

[*1] See *Guide, Section XIV* for detailed information regarding the summaries included in Table 11.

[*2] Patient months with a catheter that have limited life expectancy, including under hospice care in the current reporting month, or with metastatic cancer, end stage liver disease, coma or anoxic brain injury in the past 12 months, were excluded.

[*3] Includes patients with an autogenous arteriovenous (AV) fistula as the sole means of vascular access. SFR is calculated as an adjusted rate of AV fistula in use reported in 11c; not shown if fewer than 11 eligible adult HD patients.

[*4] Includes patients using a catheter continuously for three months or longer. Patients with other or missing access types (11c) are also counted as catheter in use in the numerator. Long-term catheter rate (11g) values in 2020 were calculated for quarter 4 only due to data limitations.

[*5] Includes all patients with fistulae, regardless of whether or not they received their hemodialysis treatments using their fistulae.

[*6] Compared to U.S. value for that year: 2.56 (2020), 2.60 (2021), 2.46 (2022), and 2.45 (2023).

Dialysis Facility Report for Fiscal Year 2025

SAMPLE Dialysis Facility State: XX Network: 99 CCN: SAMPLE

TABLE 12: Comorbidities Reported on Inpatient Medicare Claims for Medicare Dialysis Patients Treated as of December 31st of Each Year^{*1}, 2020-2023

Measure Name	This Facility				Regional Averages ^{*A} , 2023		
	2020	2021	2022	2023	State	Network	U.S.
12a Medicare dialysis patients on 12/31 (n)	48	46	45	44	45.5	45.6	45.6
12b Comorbidity (% yes of 12a)							
Infections							
AIDS/HIV positive	0.7	0.7	0.7	0.7	0.8	0.8	0.8
Intravascular/implanted device-related ^{*2}	4.7	4.9	5.0	4.9	4.8	4.9	4.9
Hepatitis B	0.4	0.4	0.4	0.4	0.4	0.4	0.5
Hepatitis other	1.8	1.7	1.6	1.4	1.5	1.5	1.5
Metastatic	1.3	1.4	1.5	1.6	1.6	1.6	1.6
Pneumonia	3.4	3.3	3.5	3.7	3.7	3.7	3.8
Tuberculosis	0.2	0.2	0.2	0.3	0.2	0.2	0.3
Other	18.5	18.5	18.8	18.9	18.8	18.7	19.1
Cardiovascular							
Cardiac arrest	0.9	1.0	1.0	0.9	0.9	0.9	1.0
Cardiac dysrhythmia	18.6	19.3	19.4	19.9	19.9	19.9	19.9
Cerebrovascular disease	7.2	7.3	7.5	7.7	7.8	7.8	7.9
Congestive heart failure	29.7	30.8	31.4	32.0	32.2	32.1	32.2
Ischemic heart disease	25.9	26.5	26.7	26.7	26.8	26.8	26.9
Myocardial infarction	6.8	7.6	8.0	8.3	8.4	8.4	8.6
Peripheral vascular disease ^{*3}	16.6	17.1	17.1	17.4	17.5	17.5	17.8
Other							
Alcohol dependence	1.4	1.4	1.4	1.5	1.4	1.4	1.5
Anemia	2.6	3.0	3.3	3.3	3.3	3.3	3.3
Cancer	3.2	3.5	3.6	3.7	3.8	3.7	3.8
Chronic obstructive pulmonary disease	14.7	14.7	14.8	15.0	15.1	15.1	14.9
Diabetes	35.9	36.8	37.0	37.0	37.3	37.3	37.6
Drug dependence	1.2	1.3	1.2	1.3	1.3	1.2	1.3
Gastrointestinal tract bleeding	2.9	3.1	3.1	3.1	3.1	3.1	3.2
Hyperparathyroidism	19.5	20.6	21.1	21.9	22.1	21.9	21.8
12c Average number of comorbid conditions	2.2	2.3	2.3	2.3	2.3	2.3	2.3

n/a = not applicable

[*A - *F] See **Appendix: Table Footnotes** on page 28.

[*1] See *Guide, Section XV* for detailed information regarding the summaries included in Table 12. Based on patients with Medicare as primary insurer on 12/31 each year.

[*2] This category includes bloodstream and other infections related to intravascular access and other implanted devices, not limited to dialysis access.

[*3] Peripheral vascular disease includes venous, arterial and nonspecific peripheral vascular diseases.

Dialysis Facility Report for Fiscal Year 2025

SAMPLE Dialysis Facility State: XX Network: 99 CCN: SAMPLE

TABLE 13: Facility Information ^{*1}, 2023

Measure Name	This Facility 2023	Regional Averages ^{*A} , 2023		
		State	Network	U.S.
13a Organization	SAMPLE MEDICAL CARE(SMC)			
13b Ownership	Profit			
13c Initial Medicare certification date	01/01/2016			
13d Number of stations	17			
13e Services provided	Unavailable			
13f Shifts after 5:00 pm	Yes			
13g Dialyzer Reuse	Yes			
13h CMS Certification Numbers (CCN) included in this report	999999			
13i National Provider Identifier (NPI)	1234569874			
<i>Long Term Care (LTC)</i>				
13j Dialysis facility located in a Skilled Nursing Facility (SNF)	Yes			
13k Services provided in LTC facility by non-SNF based facility	None			
<i>Patient Placement</i>				
13l Patients treated during year from AFS Form-2744 (n)	101	100.9	101.0	101.2
13m Transferred into facility (% of 13l)	18.4	18.1	18.1	17.9
13n Transferred out of facility (% of 13l)	19.7	18.7	18.7	18.5
13o Patients treated on 12/31 (n)	66	n/a	n/a	n/a
13p Medicare eligibility status (% of 13o; sums to 100% ^{*B})		n/a	n/a	n/a
Medicare	81.9	82.0	82.0	81.2
Medicare application pending	0.9	0.7	0.7	0.7
Non-Medicare	17.3	17.3	17.3	18.1
<i>Survey and Certification ^{*2}</i>				
13q Date of last survey	01/03/2018			
13r Type of survey	Unknown			
13s Compliance condition after survey	Meets Requirements			
13t Number of CFC deficiencies cited	0	0.2	0.2	0.2
13u Number of Standard deficiencies cited	4	4.3	4.3	4.3

n/a = not applicable

[*A - *F] See **Appendix: Table Footnotes** on page 28.

[*1] See *Guide, Section XVI* for detailed information regarding the summaries included in Table 13 Information based on data reported in EQRS as of May 2024. If missing, data were not available.

[*2] Data on this section are from the facility's latest survey since January 2009 according to information reported in QIES as of early June 2024.

Dialysis Facility Report for Fiscal Year 2025

SAMPLE Dialysis Facility State: XX Network: 99 CCN: SAMPLE

TABLE 14: Selected Measures for Dialysis Patients under Age 18^{*1}, 2020-2023[^]

Measure Name	This Facility				Regional Averages ^{*A} , 2023		
	2020 [^]	2021	2022	2023	State	Network	U.S.
<i>Patient Characteristics</i>							
14.1a	Patients treated on 12/31 (n)	7	7	7	7	n/a	n/a
14.1c	Age (% of 14.1a; sums to 100%)						
	< 5	24.8	24.2	23.4	24.6	26.9	27.7
	5-9	14.7	13.5	11.7	11.5	14.0	14.0
	10-14	28.2	30.5	34.9	31.4	27.9	27.1
	15-17	32.3	31.8	30.0	32.4	31.2	31.2
14.1d	Female (% of 14.1a)	41.6	43.8	41.0	38.4	41.7	41.0
14.1e	Race (% of 14.1a; sums to 100%)						
	African American	27.4	27.3	25.1	27.1	30.6	31.2
	Asian/Pacific Islander	6.2	6.4	6.7	5.6	4.0	4.1
	Native American	1.2	4.1	3.9	6.4	5.7	5.7
	White	63.0	60.3	61.8	59.2	57.7	57.0
	Other/Unknown/Missing	2.1	1.9	2.4	1.8	2.0	2.0
14.1f	Ethnicity (% of 14.1a; sums to 100%)						
	Hispanic	28.6	30.0	30.8	30.7	29.8	29.3
	Non-Hispanic	71.1	69.7	69.0	69.3	70.2	70.6
	Unknown	0.3	0.3	0.3	0.1	0.0	0.1
14.1g	Cause of ESRD (% of 14.1a; sums to 100%)						
	Diabetes	0.3	0.3	0.4	0.4	0.5	0.5
	Hypertension	2.4	1.0	2.0	2.4	2.0	1.7
	Glomerulonephritis	29.0	34.0	31.6	25.5	27.2	27.5
	Cystic Kidney	31.3	29.7	33.0	36.9	37.6	38.4
	Congenital/Hereditary	0.0	0.0	0.0	0.0	0.0	0.0
	Hemolytic Uremic Syndrome	0.0	0.0	0.0	0.0	0.0	0.0
	Other	30.4	27.8	25.9	27.9	24.2	23.5
	Unknown/Missing	6.7	7.2	7.0	7.0	8.4	8.3
14.1i	Years since start of ESRD (% of 14.1a; sums to 100%)						
	< 1	33.1	33.4	31.6	33.7	34.4	33.8
	1-2	24.3	21.1	24.3	24.6	22.3	22.7
	2-3	12.0	13.6	11.1	12.3	13.6	13.8
	3-6	13.4	16.3	16.7	14.5	15.8	15.6
	6+	17.3	15.6	16.2	14.9	13.9	14.2
14.1k	Modality (% of 14.1a; sums to 100%)						
	In-center hemodialysis	43.2	46.4	47.4	50.9	50.9	50.7
	Home hemodialysis	0.7	0.6	0.9	0.4	0.5	0.5
	Continuous ambulatory peritoneal dialysis	2.3	1.6	2.7	2.7	0.9	1.0
	Continuous cycling peritoneal dialysis	52.9	51.3	48.7	45.4	47.2	47.1
	Other modality	0.8	0.2	0.3	0.6	0.6	0.7

(continued)

Dialysis Facility Report for Fiscal Year 2025

SAMPLE Dialysis Facility State: XX Network: 99 CCN: SAMPLE

TABLE 14 (cont.): Selected Measures for Dialysis Patients under Age 18^{*1}, 2020-2023[^]

Measure Name	This Facility				Regional Averages ^{*A} , 2023			
	2020 [^]	2021	2022	2023	State	Network	U.S.	
<i>Characteristics of New Dialysis Patients</i>								
14.2a	Total number of patients with forms (n)	4	4	4	4	n/a	n/a	n/a
14.2g	Medical coverage (% of 14.2a; sums to 100%)							
	Employer group only	19.4	20.8	18.6	14.5	16.0	17.0	16.8
	Medicare (alone or combined w/ other insurance)	2.6	1.5	1.1	1.9	2.0	2.0	2.2
	Medicaid only	60.9	58.9	62.9	60.8	60.1	59.0	58.4
	Other/Unknown/None	17.1	18.8	17.4	22.8	22.0	22.0	22.6
14.2k	Number of incident hemodialysis patients (n)	2	2	2	2	n/a	n/a	n/a
14.2l	Access used at first outpatient dialysis (% of 14.2k; sums to 100%)							
	Arteriovenous fistula	0.4	1.2	3.6	0.8	1.3	1.0	1.2
	Arteriovenous graft	0.4	1.0	0.3	0.0	0.0	0.0	0.0
	Catheter	99.1	97.7	96.1	98.7	98.5	98.8	98.6
	Other/Unknown/Missing	0.1	0.0	0.0	0.5	0.2	0.2	0.2
14.2m	Arteriovenous fistulae placed (% of 14.2k)	2.2	3.5	5.0	1.5	2.1	1.9	1.9
14.2s	Pre-ESRD nephrologist care (% of 14.2a; sums to 100%)							
	No	19.9	21.8	19.9	20.9	22.2	21.5	21.9
	Yes, < 6 months	25.3	21.4	23.7	22.7	21.9	22.5	22.8
	Yes, 6-12 months	19.0	16.4	16.0	14.6	13.1	12.9	12.6
	Yes, > 12 months	32.4	34.9	34.3	35.4	35.0	35.7	35.7
	Unknown	3.4	5.4	6.2	6.4	7.7	7.3	6.9
14.2t	Informed of transplant options (% of 14.2a)	90.9	92.3	93.4	93.1	92.3	91.6	90.9
<i>Death Rates</i>								
14.3a	Patients (n)	11	11	11	11	n/a	n/a	n/a
14.3c	Deaths (n)	0	0	0	0	n/a	n/a	n/a
<i>Hospitalization Statistics</i>								
14.4a	Medicare dialysis patients (n)	4	4	3	3	n/a	n/a	n/a
14.4c	Total days hospitalized (n)	23	33	31	34	n/a	n/a	n/a
14.4i	Total admissions (n)	3	4	4	4	n/a	n/a	n/a
<i>Transplantation</i>								
14.5d	Eligible patients (n)	10	10	10	10	n/a	n/a	n/a
14.5f	First transplants (n)	2	3	2	3	n/a	n/a	n/a
<i>Waitlist</i>								
14.6b	Eligible patients-months (n) ^{*F}	62	90	93	92	n/a	n/a	n/a
14.6c	Patients-months on the waitlist (% of 14.6b)	35.7	34.9	34.9	34.2	32.4	32.0	31.1
14.6d	Patient-months on the waitlist by age (%)							
	Age < 10	36.7	34.0	30.8	30.2	28.8	28.8	28.9
	Age 10-17	42.8	42.2	43.4	40.7	37.0	35.4	34.9

(continued)

Dialysis Facility Report for Fiscal Year 2025

SAMPLE Dialysis Facility State: XX Network: 99 CCN: SAMPLE

TABLE 14 (cont.): Selected Measures for Dialysis Patients under Age 18^{*1}, 2020-2023[^]

Measure Name	This Facility				Regional Averages ^{*A} , 2023			
	2020 [^]	2021	2022	2023	State	Network	U.S.	
Hemoglobin								
14.8b	Eligible HD patient-months (n) ^{*F}	18	34	37	37	n/a	n/a	n/a
14.8c	Average hemoglobin (g/dL) (average of 14.8b)	10.9	10.7	10.8	10.8	10.7	10.8	10.9
14.8d	Hemoglobin categories (% of 14.8b; sums to 100%)							
	< 10 g/dL	23.0	22.4	20.7	21.6	21.2	20.8	20.6
	10-<11 g/dL	25.2	26.7	26.2	22.3	23.1	23.5	23.6
	11-12 g/dL	31.2	30.6	28.7	30.1	28.8	29.7	29.1
	> 12 g/dL	16.6	13.9	14.6	15.3	16.4	16.3	16.5
	Missing/Out of Range	4.1	6.4	9.8	10.7	10.5	9.7	10.2
14.8g	Eligible PD patient-months (n) ^{*F}	22	41	41	40	n/a	n/a	n/a
14.8h	Average hemoglobin (g/dL) (average of 14.8g)	10.9	10.9	11.0	10.8	10.8	10.8	10.8
14.8i	Hemoglobin categories (% of 14.8g; sums to 100%)							
	< 10 g/dL	23.8	23.7	22.0	25.3	25.7	26.1	25.2
	10-<11 g/dL	22.8	22.9	21.9	22.8	22.2	22.7	22.9
	11-12 g/dL	24.3	22.1	22.7	20.1	22.0	21.9	22.2
	> 12 g/dL	20.2	18.7	18.9	17.7	18.5	18.6	19.0
	Missing/Out of Range	9.0	12.7	14.5	14.1	11.6	10.7	10.6
Albumin								
14.9b	Eligible HD patient-months (n) ^{*F}	18	34	37	37	n/a	n/a	n/a
14.9c	Average serum albumin (g/dL) (average of 14.9b)	4.0	4.1	4.1	4.0	4.0	4.0	4.0
14.9d	Serum albumin categories (% of 14.9b; sums to 100%)							
	< 3.0 g/dL	2.0	2.3	2.1	2.0	2.7	2.3	2.7
	3.0-<3.5 g/dL	7.0	6.0	6.0	5.5	6.8	6.1	7.0
	3.5-<4.0 g/dL	23.5	26.3	22.7	24.9	27.8	28.0	28.9
	>=4.0 g/dL	63.4	58.6	59.1	56.7	51.9	53.8	51.2
	Missing	4.2	6.9	10.1	10.9	10.8	9.9	10.4
14.9l	Eligible PD patient-months (n) ^{*F}	22	41	41	40	n/a	n/a	n/a
14.9o	Average serum albumin (g/dL) (average of 14.9l)	3.7	3.8	3.7	3.7	3.7	3.7	3.7
14.9p	Serum albumin categories (% of 14.9l; sums to 100%)							
	< 3.0 g/dL	9.0	8.8	8.7	7.9	9.4	9.4	10.1
	3.0-<3.5 g/dL	16.1	15.2	14.9	14.1	16.4	16.6	17.6
	3.5-<4.0 g/dL	30.4	26.5	26.1	28.2	26.9	28.0	27.8
	>=4.0 g/dL	34.4	35.9	33.9	31.4	31.3	31.3	30.1
	Missing	10.2	13.6	16.3	18.4	16.0	14.7	14.5
Kt/V^{*2}								
14.9h	Eligible HD patient-months (n) ^{*F}	14	26	29	30	n/a	n/a	n/a
14.9j	HD: Kt/V >= 1.2 (% of 14.9h)	92.3	90.7	87.6	87.7	87.1	88.5	87.1
14.9n	PD: Kt/V >= 1.8 (% of 14.9l)	72.3	76.4	72.9	76.7	76.7	77.3	77.4
Vascular Access^{*3}								
14.11b	Eligible patient-months (n) ^{*F}	19	38	41	42	n/a	n/a	n/a
14.11c	Arteriovenous Fistula in use (%)	21.8	18.3	15.3	11.4	10.0	10.2	9.4
14.11g	Long-Term Catheter Rate	57.2	57.7	64.0	66.0	70.6	71.1	72.7

n/a = not applicable

[^, *A - *F] See **Appendix: Table Footnotes** on page 28.

[*1] See *Guide, Section XVII* for detailed information regarding the summaries included in Table 14.

[*2] Kt/V: K = dialyzer clearance of urea; t = dialysis time; V = patient's total body water. HD Kt/v summaries restricted to patients on thrice weekly in-center hemodialysis. PD Kt/V summaries select the most recent value collected within 6 months of the reporting month.

[*3] 'Arteriovenous Fistula in use' includes patients with an autogenous arteriovenous (AV) fistula as the sole means of vascular access. 'Long-Term Catheter Rate' includes patients using a catheter continuously for three months or longer. Patients with other or missing access types (11c) are also counted as catheter in the numerator.

Dialysis Facility Report for Fiscal Year 2025

SAMPLE Dialysis Facility State: XX Network: 99 CCN: SAMPLE

TABLE 15: Selected Measures for Nursing Home (NH) Dialysis Patients^{*1}, 2020-2023[^]

Measure Name	This Facility				Regional Averages ^{*A} , 2023			
	2020 [^]	2021	2022	2023	State	Network	U.S.	
<i>Patient Characteristics</i>								
15.1a	Patients treated on 12/31 (n)	14	14	15	17	n/a	n/a	n/a
15.1c	Age (% of 15.1a; sums to 100%)							
	18-64	35.2	34.3	33.0	32.7	32.5	32.4	32.5
	65+	64.8	65.7	67.0	67.3	67.5	67.5	67.4
15.1d	Female (% of 15.1a)	48.0	48.2	47.9	47.8	47.2	47.2	47.5
15.1e	Race (% of 15.1a; sums to 100%)							
	African American	34.6	35.7	35.9	36.3	35.2	35.0	36.7
	Asian/Pacific Islander	4.6	4.7	4.7	4.9	4.8	5.0	4.3
	Native American	1.1	1.1	1.3	1.7	1.8	1.7	1.7
	White	59.4	58.3	57.9	56.8	58.0	58.0	57.0
	Other/Unknown/Missing	0.2	0.2	0.2	0.2	0.3	0.3	0.2
15.1f	Ethnicity (% of 15.1a; sums to 100%)							
	Hispanic	15.6	16.0	15.7	15.9	16.2	16.1	14.6
	Non-Hispanic	84.3	83.9	84.3	84.1	83.7	83.8	85.3
	Unknown	0.1	0.0	0.0	0.1	0.1	0.1	0.1
15.1g	Cause of ESRD (% of 15.1a; sums to 100%)							
	Diabetes	56.8	55.7	54.4	53.3	53.1	53.1	52.7
	Hypertension	27.2	26.9	27.7	28.1	27.9	27.9	28.5
	Glomerulonephritis	4.5	4.6	4.5	4.6	4.4	4.4	4.4
	Other	11.2	12.4	13.1	13.5	13.9	13.9	13.8
	Unknown/Missing	0.3	0.3	0.3	0.5	0.6	0.6	0.7
15.1i	Years since start of ESRD (% of 15.1a; sums to 100%)							
	< 1	20.4	22.0	21.2	21.3	21.6	21.6	21.5
	1-2	16.4	14.7	16.1	15.5	15.5	15.5	15.5
	2-3	12.4	12.5	11.6	12.9	12.7	12.7	12.7
	3-6	25.2	25.4	24.7	24.4	24.5	24.6	24.6
	6+	25.6	25.4	26.4	25.8	25.6	25.7	25.6
15.1k	Modality (% of 15.1a; sums to 100%)							
	In-center hemodialysis	94.8	94.3	94.0	93.2	91.6	91.5	90.7
	Home hemodialysis	2.1	2.6	3.3	4.1	5.5	5.6	6.3
	Continuous ambulatory peritoneal dialysis	0.3	0.2	0.1	0.2	0.2	0.2	0.2
	Continuous cycling peritoneal dialysis	2.0	2.0	1.8	1.9	2.0	2.0	2.1
	Other modality	0.8	0.8	0.8	0.7	0.7	0.7	0.7

(continued)

Dialysis Facility Report for Fiscal Year 2025

SAMPLE Dialysis Facility State: XX Network: 99 CCN: SAMPLE

TABLE 15 (cont.): Selected Measures for Nursing Home (NH) Dialysis Patients^{*1}, 2020-2023[^]

Measure Name	2020 [^]	This Facility			Regional Averages ^{*A} , 2023			
		2021	2022	2023	State	Network	U.S.	
<i>Characteristics of New Dialysis Patients</i>								
15.2a	Total number of patients with forms (n)	5	6	6	6	n/a	n/a	n/a
15.2g	Medical coverage (% of 15.2a; sums to 100%)							
	Employer group only	3.4	3.0	2.6	2.3	2.3	2.3	2.3
	Medicare (alone or combined w/ other insurance)	78.5	77.6	80.6	81.7	82.4	82.5	83.0
	Medicaid only	12.1	12.3	11.1	11.0	10.3	10.3	9.9
	Other/Unknown/None	6.0	7.1	5.7	5.0	4.9	4.9	4.8
15.2k	Number of incident hemodialysis patients (n)	6	6	6	6	n/a	n/a	n/a
15.2l	Access used at first outpatient dialysis (% of 15.2k; sums to 100%)							
	Arteriovenous fistula	7.0	6.2	6.1	6.9	6.4	6.4	6.3
	Arteriovenous graft	2.3	1.5	2.6	2.7	2.4	2.4	2.3
	Catheter	88.8	89.9	89.2	88.0	88.5	88.6	88.6
	Other/Unknown/Missing	2.0	2.3	2.1	2.4	2.7	2.6	2.8
15.2m	Arteriovenous fistulae placed (% of 15.2k)	17.0	15.0	14.7	15.9	14.9	14.8	14.5
15.2s	Pre-ESRD nephrologist care (% of 15.2a; sums to 100%)							
	No	19.5	19.0	18.3	16.4	17.0	17.0	16.4
	Yes, < 6 months	19.4	20.5	21.2	21.5	21.7	21.7	21.9
	Yes, 6-12 months	17.3	17.6	16.6	17.8	16.3	16.2	16.2
	Yes, > 12 months	23.3	21.6	21.7	21.3	20.0	20.1	19.9
	Unknown	20.5	21.4	22.2	22.9	25.0	25.0	25.5
15.2t	Informed of transplant options (% of 15.2a)	79.6	86.3	88.6	88.7	87.9	87.7	88.1
<i>Mortality summary for all NH dialysis patients</i>								
15.3b	Patient years (PY) at risk (n)	10.1	15.3	15.7	17.3	n/a	n/a	n/a
15.3c	Deaths (n)	5	7	7	7	n/a	n/a	n/a
15.3d	Expected deaths (n)	4.1	6.0	5.6	5.6	n/a	n/a	n/a
15.3c/15.3b	Rate (deaths per 100 PYs at risk)	48.1	49.2	41.0	36.0	40.1	40.0	42.7
15.3h	SMR (15.3c/15.3d)	1.13	1.11	1.14	1.15	1.27	1.26	1.33
15.3e	Withdrawal from dialysis prior to death (% of 15.3c)	28.6	26.0	26.0	27.3	27.0	27.2	26.3
<i>Hospitalization summary for NH Medicare dialysis patients</i>								
15.4b	Patient years (PY) at risk (n)	8.9	13.4	13.7	15.0	n/a	n/a	n/a
15.4i	Total admissions (n)	27	39	38	43	n/a	n/a	n/a
15.4j	Expected total admissions (n)	18.9	25.8	26.0	29.6	n/a	n/a	n/a
15.4i/15.4b	Rate (admissions per 100 PYs at risk)	301.8	295.4	280.1	288.1	293.9	292.7	301.7
15.4k	SHR (15.4i/15.4j)	1.48	1.56	1.51	1.50	1.51	1.51	1.54
15.4o	Diagnoses associated with hospitalization (% of 15.4a)							
	Septicemia	27.7	25.7	25.2	24.7	25.0	25.0	22.3
	Acute myocardial infarction	12.0	12.4	12.3	13.0	13.1	13.1	11.4
	Congestive heart failure	49.5	47.6	49.2	49.5	49.2	49.1	44.8
	Cardiac dysrhythmia	36.0	35.3	35.2	35.0	35.3	35.2	31.7
	Cardiac arrest	4.7	4.7	4.3	4.0	4.2	4.2	3.8

(continued)

Dialysis Facility Report for Fiscal Year 2025

SAMPLE Dialysis Facility State: XX Network: 99 CCN: SAMPLE

TABLE 15 (cont.): Selected Measures for Nursing Home (NH) Dialysis Patients^{*1}, 2020-2023[^]

Measure Name	This Facility				Regional Averages ^{*A} , 2023			
	2020 [^]	2021	2022	2023	State	Network	U.S.	
<i>Comorbidities reported on Medicare claims</i>								
15.12a	Medicare dialysis patients on 12/31 (n)	12	12	13	14	n/a	n/a	n/a
15.12b	Comorbidity (% yes of 15.12a)							
Infections								
	AIDS/HIV positive	1.1	1.2	1.1	1.0	1.0	1.0	1.0
	Intravascular/implanted device-related	8.2	8.3	8.5	8.6	8.5	8.5	8.9
	Hepatitis B	0.9	0.9	0.9	0.8	0.8	0.8	0.9
	Hepatitis other	3.9	3.6	3.5	3.2	3.0	3.0	3.1
	Metastatic	3.6	3.7	4.3	4.1	4.2	4.2	4.5
	Pneumonia	9.7	9.3	9.9	10.2	10.2	10.1	10.5
	Tuberculosis	0.4	0.3	0.3	0.3	0.3	0.3	0.3
	Other	41.2	40.6	40.7	40.8	40.9	40.8	41.7
Cardiovascular								
	Cardiac arrest	2.4	2.5	2.4	2.5	2.5	2.4	2.6
	Cardiac dysrhythmia	38.2	39.1	40.0	39.8	40.0	39.9	40.3
	Cerebrovascular disease	19.3	19.2	19.9	19.9	19.8	19.7	20.1
	Congestive heart failure	55.1	55.1	57.3	57.7	57.3	57.3	58.0
	Ischemic heart disease	48.2	48.6	47.9	47.5	47.8	47.7	48.1
	Myocardial infarction	15.3	14.5	14.8	16.3	16.0	16.0	16.3
	Peripheral vascular disease	36.1	37.1	36.5	36.9	37.1	37.0	37.6
Anemia								
15.8b	Eligible adult HD patient-months (n) ^{*F}	81	168	172	191	n/a	n/a	n/a
15.8d	Hemoglobin (HD) < 10 g/dL (% of 15.8b)	30	31	31	30	30.2	30.1	30.3
15.8e	ESA prescribed (% of 15.8b)	80	81	80	80	79.9	79.9	80.0
15.8g	Eligible adult PD patient-months (n) ^{*F}	2	5	5	5	n/a	n/a	n/a
15.8i	Hemoglobin (PD) < 10 g/dL (% of 15.8g)	28	29	29	29	29.0	28.7	28.3
15.8j	ESA prescribed (% of 15.8g)	60	59	58	58	57.0	57.1	56.2
Dialysis Adequacy^{*2}								
15.9b	Eligible adult HD Kt/V patient-months (n) ^{*F}	77	159	163	181	n/a	n/a	n/a
15.9k	Kt/V (HD) < 1.2 (% of 15.9b)	3	3	3	2	2.3	2.3	2.3
15.9m	Eligible adult PD Kt/V patient-months (n) ^{*F}	1	5	5	5	n/a	n/a	n/a
15.9o	Kt/V (PD) < 1.7 (% of 15.9m)	8	11	11	10	9.0	8.9	8.9
Vascular Access^{*3}								
15.11b	Prevalent adult hemodialysis patient months (n) ^{*F}	83	175	178	192	n/a	n/a	n/a
15.11c	Arteriovenous fistula in use (% of 15.11b)	49.1	49.1	47.7	47.9	48.6	48.6	48.1
15.11g	Long-Term Catheter Rate	22.8	21.4	23.0	23.4	23.1	23.1	23.3

n/a = not applicable

[^, *A - *F] See **Appendix: Table Footnotes** on page 28.

[*1] See *Guide, Section XVIII* for detailed information regarding the summaries included in Table 15.

[*2] Kt/V summaries are supplemented with Medicare claims if missing in EQRS. HD Kt/V summaries are restricted to patients who dialyze thrice weekly. See section of Guide titled "*Determination of Thrice Weekly Dialysis*" for more information. PD Kt/V summaries select the most recent value collected within months of the reporting month.

[*3] Patient months with a catheter that have limited life expectancy, including under hospice care in the current reporting month, or with metastatic cancer, end stage liver disease, coma or anoxic brain injury in the past 12 months, were excluded. Other or missing access types are counted as catheter in use in the numerator. LTCR includes patients using a catheter continuously for three months or longer.

Appendix: Table Footnotes

This appendix provides information that applies to multiple tables.

[^] CMS Extraordinary Circumstances Exceptions: Mortality (Table 3), Hospitalization (Table 4), Transplantation (Table 5), Waitlist (Table 6), Transfusion (Table 7), and PD Infection (Table 11) summaries exclude data from March through June 2020 from all calculations. Readmission statistics (Table 4) are further limited to index discharges between January 1-30, 2020 and July-December 2020. Anemia Management (Table 8), Dialysis Adequacy (Table 9), Mineral Metabolism (Table 10), and Vascular Access (Table 11) summaries exclude data from January through June 2020 from all calculations.

[*A] Regional values are shown for the average facility. When the summary includes three- or four-years, values are shown for the average facility, annualized.

[*B] Values may not sum to exactly 100%. Refer to the appropriate section of the Guide found in the table-specific footnotes (section II) below for additional details.

[*C] Sum of counts over the three- or four-years used for calculations and should not be compared to regional averages.

[*D] This value is the ratio of observed events to expected events. This value is not shown when there are too few events to yield reliable result. Refer to the table-specific footnotes (section II) below for the criteria for when the ratio is reported.

[*E] The confidence interval range represents uncertainty in the value of the ratio due to random variation. A p-value less than 0.05 indicates that the difference between the observed and expected events is probably real and is not due to random chance alone. A p-value greater than or equal to 0.05 indicates that the difference could plausibly be due to random chance.

[*F] A patient may be counted up to 12 times per year.

SAMPLE